Today's Daily Dose brings you news about Gilead reportedly mulling a stake in Arcus; disappointing results of Oragenics' oral mucositis trial; FDA approval of the first therapy for low-grade upper tract urothelial cancer and Vanda initiating a phase III trial in the treatment of neurogenic inflammation of the lung secondary to COVID-19.
from RTT - Biotech https://ift.tt/2VvbuhW
via IFTTT
No comments:
Post a Comment